| CAS NO: | 130370-60-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 477.64 |
|---|---|
| Formula | C23H31N3O4S2 |
| CAS No. | 130370-60-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 96 mg/mL (201.0 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | 30% propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL |
| Synonyms | BB94; Batimastat; BB 94; BB-94. IUPAC/Chemical Name: (2S,3R)-N-Hydroxy-N'-[(2S)-1-methylamino-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide. InChi Key: XFILPEOLDIKJHX-QYZOEREBSA-N InChi Code: InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1 SMILES Code: O=C(NO)[C@@H](CSC1=CC=CS1)[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(NC)=O)=O |
| In Vitro | In vitro activity: Batimastat (BB-94) is a potent, broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. Batimastat exhibits an unexpected binding geometry, with the thiophene ring deeply inserted into the primary specificity site. Kinase Assay: Batimastat is a potent broad spectrum MMP inhibitor with IC50 of 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3, respectively. Cell Assay: In vitro proliferation in the presence of batimastatwas assessed by the MTT absorbance assay. The effect of batimastat on the in vitro growth of C170HM2 and AP5LV in both serum-free and scrum-containing culture media was determined three times. Batimastat had no significant effect on the growth of either cell line. |
|---|---|
| In Vivo | Batimastat can inhibit metastatic spread and growth of B16-BL6 murine melanoma. In an orthotopic colon tumor model in mice, timastat treatment results in inhibition of primary tumor growth (by 50%), local/regional spread(from 67% to 35%), and distant metastasis(from 30% to 10%). Batimastat reduces in vivo growth of experimental hemangiomas, most probably by blocking endothelial cell recruitment by the transformed cells or by interfering with cell organization in vascular structures. |
| Animal model | Nude mice |
| Formulation & Dosage | Dissolved in PBS containing 0.01% Tween 2O; 30 mg/kg; i.p. injection |
| References | Int J Cancer. 1994 Aug 1;58(3):460-4; Cancer Res. 1994 Sep 1;54(17):4726-8; J Natl Cancer Inst. 1995 Feb 15;87(4):293-8. |
|
|
|
|
m.cnreagent.com
